Interleukin-32 stimulates osteosarcoma cell invasion and motility via AKT pathway-mediated MMP-13 expression

Zhou,Yanhong; Hu,Zhaohui; Li,Ningning; Jiang,Renjie

doi:10.3892/ijmm.2015.2159

Interleukin-32 stimulates osteosarcoma cell invasion and motility via AKT pathway-mediated MMP-13 expression

Authors:
- Yanhong Zhou
- Zhaohui Hu
- Ningning Li
- Renjie Jiang
View Affiliations

Affiliations: Department of Clinical Laboratory, The People's Hospital of Liuzhou, Liuzhou 545006, P.R. China, Department of Spine Surgery, The People's Hospital of Liuzhou, Liuzhou 545006, P.R. China
Published online on: March 31, 2015 https://doi.org/10.3892/ijmm.2015.2159
Pages: 1729-1733

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a pro-inflammatory cytokine, interleukin-32 (IL-32) is reported to play an important role in tumor development and progression. However, its effects on the invasion and motility of osteosarcoma cells remain elusive. The aim of the present study was to determine the molecular mechanisms of IL-32 in osteosarcoma cells using RT-PCR and western blot analysis. The results showed that IL-32 stimulation dose-dependently promoted the invasion and motility of osteosarcoma cells. Knockdown of endogenous IL-32 by siRNA inhibited osteosarcoma cell invasion and motility. Moreover, IL-32 induced the activation of AKT in a time‑dependent manner. IL-32 stimulation was also capable of increasing the expression and secretion of matrix metalloproteinase (MMP)-13, which is involved in tumor invasion and metastasis. In addition, blockade of AKT activation suppressed IL-32-mediated invasion, motility and MMP-13 upregulation in osteosarcoma cells. Taken together, our results suggest that IL-32 stimulation promotes the invasion and motility of osteosarcoma cells, possibly via the activation of AKT and the upregulation of MMP-13 expression. Thus, IL-32 may serve as a marker for diagnosis, as well as for the treatment of osteosarcoma.

View Figures

View References

1	Heare T, Hensley MA and Dell’Orfano S: Bone tumors: osteosarcoma and Ewing’s sarcoma. Curr Opin Pediatr. 21:365–372. 2009. View Article : Google Scholar : PubMed/NCBI
2	Broadhead ML, Clark JC, Myers DE, Dass CR and Choong PF: The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
3	Kakhki VR, Anvari K, Sadeghi R, Mahmoudian AS and Torabian-Kakhki M: Pattern and distribution of bone metastases in common malignant tumors. Nucl Med Rev Cent East Eur. 16:66–69. 2013. View Article : Google Scholar : PubMed/NCBI
4	Wu PK, Chen WM, Chen CF, Lee OK, Haung CK and Chen TH: Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol. 39:514–522. 2009. View Article : Google Scholar : PubMed/NCBI
5	Sheu BC, Chang WC, Cheng CY, Lin HH, Chang DY and Huang SC: Cytokine regulation networks in the cancer microenvironment. Front Biosci. 13:6255–6268. 2008. View Article : Google Scholar : PubMed/NCBI
6	Wilson J and Balkwill F: The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol. 12:113–120. 2002. View Article : Google Scholar : PubMed/NCBI
7	Kim SH, Han SY, Azam T, Yoon DY and Dinarello CA: Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 22:131–142. 2005.PubMed/NCBI
8	Netea MG, Azam T, Ferwerda G, et al: IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA. 102:16309–16314. 2005. View Article : Google Scholar : PubMed/NCBI
9	Choi JD, Bae SY, Hong JW, et al: Identification of the most active interleukin-32 isoform. Immunology. 126:535–542. 2009. View Article : Google Scholar :
10	Yagi Y, Andoh A, Imaeda H, et al: Interleukin-32α expression in human colonic subepithelial myofibroblasts. Int J Mol Med. 27:263–268. 2011.
11	Yousif NG, Al-Amran FG, Hadi N, Lee J and Adrienne J: Expression of IL-32 modulates NF-kappaB and p38 MAP kinase pathways in human esophageal cancer. Cytokine. 61:223–227. 2013. View Article : Google Scholar
12	Lee HJ, Liang ZL, Huang SM, et al: Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma. Oncol Lett. 3:490–496. 2012.PubMed/NCBI
13	Joosten LA, Heinhuis B, Netea MG and Dinarello CA: Novel insights into the biology of interleukin-32. Cell Mol Life Sci. 70:3883–3892. 2013. View Article : Google Scholar : PubMed/NCBI
14	Kang YH, Park MY, Yoon DY, et al: Dysregulation of over-expressed IL-32alpha in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-kappaB and Bcl-2. Cancer Lett. 318:226–233. 2012. View Article : Google Scholar
15	Oh JH, Cho MC, Kim JH, et al: IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals. Oncogene. 30:3345–3359. 2011. View Article : Google Scholar : PubMed/NCBI
16	Chang CJ, Chien Y, Lu KH, et al: Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells. Biochem Biophys Res Commun. 415:245–251. 2011. View Article : Google Scholar : PubMed/NCBI
17	Nold-Petry CA, Rudloff I, Baumer Y, et al: IL-32 promotes angiogenesis. J Immunol. 192:589–602. 2014. View Article : Google Scholar :
18	Ishigami S, Arigami T, Uchikado Y, et al: IL-32 expression is an independent prognostic marker for gastric cancer. Med Oncol. 30:4722013. View Article : Google Scholar : PubMed/NCBI
19	Sorrentino C and Di Carlo E: Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med. 180:769–779. 2009. View Article : Google Scholar : PubMed/NCBI
20	Park JS, Choi SY, Lee JH, et al: Interleukin-32beta stimulates migration of MDA-MB-231 and MCF-7 cells via the VEGF-STAT3 signaling pathway. Cell Oncol (Dordr). 36:493–503. 2013. View Article : Google Scholar
21	Tsai CY, Wang CS, Tsai MM, et al: Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res. 20:2276–2288. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zeng Q, Li S, Zhou Y, et al: Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine. 65:24–32. 2014. View Article : Google Scholar
23	Mabilleau G and Sabokbar A: Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS One. 4:e41732009. View Article : Google Scholar : PubMed/NCBI
24	Cho KS, Park SH, Joo SH, Kim SH and Shin CY: The effects of IL-32 on the inflammatory activation of cultured rat primary astrocytes. Biochem Biophys Res Commun. 402:48–53. 2010. View Article : Google Scholar : PubMed/NCBI
25	Felaco P, Castellani ML, De Lutiis MA, et al: IL-32: a newly-discovered proinflammatory cytokine. J Biol Regul Homeost Agents. 23:141–147. 2009.PubMed/NCBI
26	Brader S and Eccles SA: Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori. 90:2–8. 2004.PubMed/NCBI
27	Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP and Lopez-Otin C: Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors. APMIS. 107:45–53. 1999. View Article : Google Scholar : PubMed/NCBI
28	Ye Z, Jingzhong L, Yangbo L, Lei C and Jiandong Y: Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression. Oncol Res. 21:201–207. 2014. View Article : Google Scholar : PubMed/NCBI
29	Osaki M, Takeshita F, Sugimoto Y, et al: MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther. 19:1123–1130. 2011. View Article : Google Scholar : PubMed/NCBI
30	Ma O, Cai WW, Zender L, et al: MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 69:2559–2567. 2009. View Article : Google Scholar : PubMed/NCBI